IceCure Medical Ltd.
No SEC Form 4 filings for $ICCM in the last 30 days.
See all $ICCM insider activity →IceCure Medical (ICCM) received IRB approval for its ChoICE study on ProSense cryoablation system for low-risk breast cancer. The study will evaluate the system in patients aged 70+ at West Cancer Center. ProSense is FDA-approved for this use. Earlier trial showed 3.1% local recurrence rate. ICCM stock closed at $2.52, up 0.40% in pre-market.
IceCure Medical (ICCM) received IRB approval from West Cancer Center for its ChoICE study on ProSense® cryoablation for low-risk breast cancer. The study, expected to enroll patients soon, aims to gather real-world data on the treatment. ProSense® is FDA-approved for women 70+ with low-risk tumors. The study will involve 30 sites and 400 patients, expanding access to cryoablation.
Icecure Medical (ICCM) reported a 45% revenue surge in Q2 2026. The company expressed confidence in meeting FDA milestones for the CHoICE study, with plans to enroll 80 patients by March 2027. The US active commercial installed base exceeds 30 sites, up 70% since FDA clearance. Gross margin was affected by exchange rate fluctuations. The company did not provide forward-looking revenue projections.
Over the past 7 days, alphai's AI scored 4 news stories mentioning ICCM (IceCure Medical Ltd.). Coverage has skewed bullish: 3 bullish, 1 neutral, and 0 bearish.
Recent ICCM coverage spans technology, earnings and regulation.
The approval enables a new real‑world data study, potentially expanding market adoption of ProSense.
Positive regulatory step may boost future sales and investor sentiment for IceCure.
Positive enrollment guidance may boost near‑term share price as the company moves toward commercial scale.
Revenue growth and new financing improve short-term liquidity but net loss and cash runway raise going‑concern concerns.
The PR is supportive for ProSense adoption, but it is primarily promotional around already-disclosed regulatory and trial context rather than a new approval or datapoint.
alphai scores every news story that mentions ICCM with an AI model for sentiment and relevance, and aggregates insider trades from IceCure Medical Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
IceCure Medical (ICCM) received IRB approval for its ChoICE study on ProSense cryoablation system for low-risk breast cancer. The study will evaluate the system in patients aged 70+ at West Cancer Center. ProSense is FDA-approved for this use. Earlier trial showed 3.1% local recurrence rate. ICCM stock closed at $2.52, up 0.40% in pre-market.
1 min readIceCure Medical (ICCM) received IRB approval from West Cancer Center for its ChoICE study on ProSense® cryoablation for low-risk breast cancer. The study, expected to enroll patients soon, aims to gather real-world data on the treatment. ProSense® is FDA-approved for women 70+ with low-risk tumors. The study will involve 30 sites and 400 patients, expanding access to cryoablation.
2 min readIcecure Medical (ICCM) reported a 45% revenue surge in Q2 2026. The company expressed confidence in meeting FDA milestones for the CHoICE study, with plans to enroll 80 patients by March 2027. The US active commercial installed base exceeds 30 sites, up 70% since FDA clearance. Gross margin was affected by exchange rate fluctuations. The company did not provide forward-looking revenue projections.
2 min readIceCure Medical (ICCM) reported $1.8M in H1 2026 revenue, up 45% YoY. U.S. revenue grew 64% post-FDA clearance. Gross profit rose 57% to $548K, but net loss widened to $8.8M. Cash increased to $12M after $8.5M Q2 financing. Management highlighted growth in system and disposable probe sales, U.S. expansion, and the CHOICE study.
3 min readIceCure Medical (NASDAQ: ICCM) said two peer-reviewed publications support cryoablation for breast cancer de-escalation. The first cites FDA marketing authorization for ProSense and inclusion in updated ASBrS guidelines, referencing ICE3 five-year results with a 3.1% IBTR rate. The second discusses cryoablation for axillary lymph node metastases.
2 min readIceCure Medical (ICCM) reported six-month results ended June 30, 2026. Revenue rose 45% year over year to $1.8 million from $1.24 million. Gross profit increased to $548,000 from $349,000, helped by higher ProSense system and disposable probe sales. Cash was $12.0 million. The company said U.S. footprint grew 70% and it is advancing its CHoICE post-marketing study.
4 min readIceCure Medical reported Q2 2026 revenue up about 45%, driven by higher system sales and disposable probe use. Gross margin rose to 30% despite FX headwinds. U.S. footprint grew about 70% after FDA clearance. Management expects first CHOICE study patient enrollment in 3 to 4 weeks and 80 patients by March 2027. Cash was about $12M after a Q2 financing raising about $8.5M gross.
7 min readIceCure Medical Ltd. (Nasdaq: ICCM) said Adventist Health Glendale in California signed an agreement and received IRB approval to become the first U.S. site enrolling patients in its post-marketing ChoICE study for ProSense cryoablation in low-risk breast cancer. The study will enroll up to 400 patients across multiple sites to generate real-world data after FDA marketing authorization in Oct. 2025.
3 min readIceCure Medical (Nasdaq: ICCM) said the Society of Interventional Oncology submitted a petition to the NCCN Breast Cancer Guidelines Panel to add percutaneous cryoablation without surgical excision as a Category 2B option. The proposal targets patients 70+ meeting specific low-risk tumor criteria, and 50-69 poor surgical candidates or surgery decliners with cryoablation plus whole-breast radiation and endocrine therapy, citing FDA clearance of its ProSense system in Oct 2025.
3 min readIceCure Medical (ICCM) said adoption of its ProSense cryoablation system is increasing in Brazil after FDA marketing authorization for early-stage, low-risk breast cancer. The company cites existing ANVISA approval and expanding use across several cancers, with trials underway (750-patient Brazil, 900-patient France) comparing outcomes to standard care. ICCM closed July 2 at $5.36.
4 min read
